anti-nectin-4 antibody-drug conjugate SHR-A2102

An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via a cleavable linker, to a topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-nectin-4 ADC SHR-A2102 targets and binds to nectin-4 expressed on tumor cells. Upon binding, internalization and linker cleavage, topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing nectin-4. Nectin-4 is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue.